Opendata, web and dolomites

BiCyHePepDi

Bicyclic hetero peptidimer - a novel molecule format for therapeutic peptides

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "BiCyHePepDi" data sheet

The following table provides information about the project.

Coordinator
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://lppt.epfl.ch/page-51483-en.html
 Total cost 131˙564 €
 EC max contribution 131˙564 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2017-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 131˙564.00

Map

 Project objective

The main objective of the proposed project is the establishment of a generically-applicable new therapeutic molecule format, which will be referred as “bicyclic hetero peptidimer”. We propose linking two bicyclic peptides that bind to the same target but in different locations to generate an antagonist with high affinity and activity. This idea borrows from antibody therapeutics that typically have two arms that can bind to the target, increasing local concentration and improving the overall affinity of the therapeutic. In a second step, we will tether our active bicyclic hetero peptidimer to a known albumin-binding peptide to improve plasma half-life. This has previously been shown to increase the half-life of bicyclic peptides by nearly 50-fold in mice. In the proposed project we will use the new peptide format for the development of picomolar FXII inhibitors. Uncontrolled FXII activity is the cause for the severe disease hereditary angioedema (HEA), where currently no satisfactory therapeutic options are available. This general concept is in no way limited to any particular target, and has the potential to be generally applicable to any peptide-based therapeutics to increase both affinity as well as half-life, two of the major drawbacks to current peptide-based treatment strategies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BICYHEPEPDI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BICYHEPEPDI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

Goc-MM (2019)

Human gut microbiota on gut-on-a-chip

Read More  

AMPLE (2019)

A Study of the Notion of Ampleness in Model Theory and Tits Buildings

Read More